RFC and MTHFR SNPs & hENT1- dCK Expression as Prognostic Factors in ALL & hENT1- dCK Expression as Prognostic Factors in AML
|ClinicalTrials.gov Identifier: NCT01307241|
Recruitment Status : Unknown
Verified November 2013 by DR. MYRNA CANDELARIA, National Institute of Cancerología.
Recruitment status was: Active, not recruiting
First Posted : March 2, 2011
Last Update Posted : November 15, 2013
|Condition or disease|
|Acute Lymphoblastic Leukemia. Acute Myeloblastic Leukemia|
|Study Type :||Observational|
|Estimated Enrollment :||50 participants|
|Official Title:||Evaluation of RFC Transporter & MTHFR SNP's, as Well as hEN1 and DCK Expression as Prognostic Factors in Patients With Acute Lymphoblastic Leukemia.|
|Study Start Date :||December 2010|
|Estimated Primary Completion Date :||December 2014|
|Estimated Study Completion Date :||December 2015|
Adult patients with ALL attending at the Instituto Nacional de Cancerologia Mexico.
- To evaluate clinical response [ Time Frame: December 2012 ]To evaluate clinical response after ending Hyper-CVAD schema for ALL patients. To evaluate clinical response & DFS in relation with hENT1 & dCK expression levels in AML patients.
- Clinical responses in relation with SNP's or gene expression [ Time Frame: clinical response. ]
Biospecimen Retention: Samples With DNA
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01307241
|Instituto Nacional de Cancerologia|
|Mexico city, DF, Mexico, 14080|
|Principal Investigator:||myrna candelaria, md||Instituto Nacional de Cancerología Mexico|